Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT)

Robert Pytlik, Kamila Polgarova, MD, Marie Trnkova, Mgr, Pavel Klener, Jr., MD PhD Assoc Prof, Petra Blahovcova, Mgr, Blanka Vackova, MD, Eva Konířová, MD, Benešová Kateřina, MD PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 3289.

https://doi.org/10.1182/blood.V130.Suppl_1.3289.3289

Published: 2017

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

Magdalena Klanova, Lucie Lorkova, MSc, Ondrej Vit, MSc, Bokang Maswabi, MD, Jan Molinsky, MD, Jana Pospisilova, MSc, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Martin Vokurka, MD, PhD, Jiri Petrak, MSc, PhD, Pavel Klener, Jr., MD, PhD

Blood (2013) 122 (21): 3835.

https://doi.org/10.1182/blood.V122.21.3835.3835

Published: 2013

Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 647.

https://doi.org/10.1182/blood.V122.21.647.647

Published: 2013

Journal Articles

CD31/PECAM-1 Is Overexpressed On Mantle-Cell Lymphoma (MCL) Primary Cells and Positively Regulates Engraftment and Growth of MCL Cell Lines in Immunodeficient Mice.

Jan Molinsky, MD, Magdalena Klanova, MD, Bokang Maswabi, MD, Josef Karban, MD, Martin Spacek, MD, Marek Trneny, MD, Emanuel Necas, MD, PhD, Jan Zivny, MD, PhD, Pavel Klener, Jr., MD, PhD

Blood (2012) 120 (21): 2681.

https://doi.org/10.1182/blood.V120.21.2681.2681

Published: 2012

Journal Articles

Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.

John Miller, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Ping-Chiao Tsai, PhD, Pavel Klener, Jr., MD, PhD, Francisco Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2012) 120 (21): 2756.

https://doi.org/10.1182/blood.V120.21.2756.2756

Published: 2012

Journal Articles

Mouse Models of Human Mantle Cell Lymphoma for the Study of Disease Biology and for Pre-Clinical Assessment of Experimental Treatment Approaches.

Pavel Klener, Jr., MD, PhD, Magdalena Klanova, MD, Tomas Soukup, MD, Jan Molinsky, MD, Jan Zivny, MD, PhD, Marek Trneny, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD, Emanuel Necas, MD, PhD

Blood (2012) 120 (21): 2759.

https://doi.org/10.1182/blood.V120.21.2759.2759

Published: 2012

Journal Articles

Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.

Natalie M Czuczman, Matthew J. Barth, MD, Richa Dwar, Cory Mavis, BSc, MSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 2761.

https://doi.org/10.1182/blood.V120.21.2761.2761

Published: 2012

NARROW

Destiny of Elderly Patients with Lymphoma Indicated for Autologous Stem Cell Transplantation (ASCT)

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

CD31/PECAM-1 Is Overexpressed On Mantle-Cell Lymphoma (MCL) Primary Cells and Positively Regulates Engraftment and Growth of MCL Cell Lines in Immunodeficient Mice.

Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models.

Mouse Models of Human Mantle Cell Lymphoma for the Study of Disease Biology and for Pre-Clinical Assessment of Experimental Treatment Approaches.

Evaluation of the Anti-Tumor Activity of MLN4924, A Novel NEDD8 Activating Enzyme Inhibitor, in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only